Evommune (NYSE: EVMN) releases Q3 2025 results and business update press

Rhea-AI Filing Summary

Evommune, Inc. filed a current report to share that it has issued a press release with a business update and its financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference. The company notes that this information is being furnished rather than filed, which means it is not subject to certain liability provisions under the securities laws and is not automatically included in other SEC filings unless specifically referenced.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0002044725false00020447252025-12-112025-12-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 11, 2025

Evommune, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	001-42938	85-0742575
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
1841 Page Mill Road, Suite 100 Palo Alto, CA		94304
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (925) 247-4487

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	EVMN	The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On December 11, 2025, Evommune, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the third quarter ended September 30, 2025 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1 and is incorporated by reference.

The information in this Item 2.02, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as otherwise expressly stated in any such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release dated December 11, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Evommune, Inc.
Date: December 11, 2025		By:	/s/ Luis Peña
			Luis Peña
			President and Chief Executive Officer

2

FAQ

What did Evommune (EVMN) announce in its latest SEC report?

Evommune announced that it issued a press release providing a business update and its financial results for the third quarter ended September 30, 2025, which is attached as Exhibit 99.1.

Which period do Evommune (EVMN)'s newly reported results cover?

The financial results referenced in the report cover Evommune's third quarter, which ended on September 30, 2025.

Where can investors find Evommune (EVMN)'s detailed Q3 2025 results?

Detailed results are contained in the press release furnished as Exhibit 99.1 to the current report.

Is Evommune's Q3 2025 press release considered filed with the SEC?

No. The company states that the information in Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act.

Who signed Evommune (EVMN)'s current report providing the Q3 2025 update?

The report was signed on behalf of Evommune, Inc. by Luis Peña, the President and Chief Executive Officer.

What exhibits are included with Evommune (EVMN)'s current report?

The report includes Exhibit 99.1, a press release dated December 11, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.